Real-world data reveals outcomes of tucatinib combo after T-DXd in advanced breast cancer
NCT ID NCT06961331
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at medical records of 86 people with HER2+ metastatic breast cancer to see how well a combination of tucatinib, trastuzumab, and capecitabine worked after they had already received a treatment called T-DXd. The goal was to measure things like time until the next treatment or death. The study did not give any new treatment but instead analyzed existing data to understand real-world outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HER2+ ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
New York, New York, 10001, United States